Search Results - c

1424 Results

Sort By:

Acyloxyacyl Hydrolase (AOAH) and Methods of Use

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of AOAH as a cancer immunotherapy. Description of Technology: Immune CheckPoint Inhibitors (ICIs) and T-cell based therapies are part of the emerging immunology-based therapies being used to treat cancers. However, the efficacy...

Published: 9/30/2025 | Inventor(s): Peng Jiang, Lanqi Gong

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) for use in near-infrared photoimmunotherapy (NIR-PIT) in the treatment of cancer. Description of Technology: Near-infrared photoimmunotherapy (NIR-PIT) is a method of...

Published: 9/30/2025 | Inventor(s): Peter Choyke, Hisataka Kobayashi, Hideo Takakura, Daiki Hara

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Humanized Monoclonal Antibodies Specific Against Human Soluble Tissue Factor (hsTF) as Diagnosis, Prevention and Therapeutic Agents for Thrombosis

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel humanized monoclonal antibody (58B3) that selectively targets a newly identified soluble Tissue Factor (sTF) to diagnose, prevent and treat pathological thrombosis associated with inflammation, viral/bacterial infection, sepsis and cancer...

Published: 9/29/2025 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

Combination PDL1 and TGF Beta Blockade in Patients with HPV-Associated Malignancies

Summary: The National Cancer Institute (NCI) seeks collaborations and licensees for a method to block PD-L1 and TGF-beta for the treatment of HPV-associated malignancies. Description of Technology: Advanced or relapsed human papillomavirus (HPV)-associated cancers are incurable and many of these diseases do not have a standard second line therapy....

Published: 9/29/2025 | Inventor(s): Julius Strauss, James Gulley, Christian Hinrichs

Keywords(s):

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein

Summary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many...

Published: 9/29/2025 | Inventor(s): Jeffrey Schlom, Kwong-Yok Tsang

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description...

Published: 9/29/2025 | Inventor(s): Jeffrey Schlom, Duane Hamilton, Claudia Palena, Renee Donahue

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2

Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291...

Published: 9/29/2025 | Inventor(s): Karl Pfeifer, Bjorn Knollmann

Keywords(s):

Category(s): TherapeuticArea > Rare/Neglected Diseases, Application > Research Materials, Collaboration Sought > Licensing

Innovative Antibody Conjugation Technology for Therapeutic and Diagnostic Applications

This pioneering technology introduces a novel method for conjugating antibodies, designed to dramatically enhance their therapeutic and diagnostic performance. By improving both binding efficiency and target specificity, this approach overcomes critical limitations of existing antibody-based therapies and imaging tools. The result is a versatile platform...

Published: 9/22/2025 | Inventor(s): Frank Borris, Parinaz Fathi, Kaitlyn Sadtler

Keywords(s):

Category(s): Application, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease

Advanced Biodegradable Polymers for Medical Devices

This breakthrough technology features advanced biodegradable polymers engineered specifically for medical device applications. Designed to safely degrade within the body, these polymers eliminate the need for surgical removal, significantly reducing the risk of long-term complications and enhancing overall patient safety. The polymers’ controlled...

Published: 9/22/2025 | Inventor(s): Ravi Lokwani, Kaitlyn Sadtler

Keywords(s):

Category(s): Application > Medical Devices, Application > Therapeutics, ResearchProducts > Human Cell Lines

Rapid Spectral Unmixing Using Spectrally Interpolated Background Reduction (SIBR) for Fluorescence Imaging

This breakthrough technology introduces Spectrally Interpolated Background Reduction (SIBR), a novel process that enables the rapid and efficient calculation of fluorescence signals from individual probes in complex, multi-labeled samples. Unlike traditional methods that require extensive computational power, SIBR provides real-time unmixing of signals...

Published: 9/22/2025 | Inventor(s): Harshad Vishwasrao

Keywords(s):

Category(s): Application > Medical Devices, Application > Research Materials, Application > Diagnostics

1 2 3 4 5 6 7 8 9 10 ...